The Standard of Care for EGFR Exon 20 Insertion+ Lung Cancer
In Partnership With
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the current standard of care for EGFR exon 20 insertion-mutated lung cancer.
Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the current standard of care for EGFR exon 20 insertion-mutated lung cancer.
According to Spira, the current standard of care for this disease is chemotherapy alone. However, 1 new drug is in the pipeline for approval, the tyrosine kinase inhibitor (TKI) known as mobocertinib. A monoclonal antibody known as amivantamab (Rybrevant) was recently granted FDA approval for the treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 20 insertion mutations. The approval was the result of positive data from the phase 1 CHRYSALIS clinical trial (NCT02609776).
Both agents have reasonable response rates. Mobocertinib has a response rate in the mid to high 20% range as a second-line therapy. Amivantamab offers a slightly higher response rate, says Spira. Both drugs also appear to be well tolerated
FDA Clears Lazertinib/Amivantamab for First-Line EGFR-Mutated NSCLC
August 20th 2024Lazertinib and amivantamab as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer with specific EGFR mutations demonstrated superior efficacy compared with standard treatment.
Read More
Osimertinib Offers New Standard of Care in Stage III EGFR-Mutated NSCLC
August 6th 2024Suresh S. Ramalingam, MD, discussed the practice-changing findings and implications of the phase 3 LAURA study investigating osimertinib for the treatment of patients with EGFR-mutated non–small cell lung cancer.
Read More
